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Publiekssamenvatting 
Analyse van klachten na sterilisatie met Essure® in Nederland 
Gezondheidsproblemen na een niet chirurgische sterilisatie-ingreep 
bij vrouwen  
Het RIVM heeft klachten geanalyseerd van vrouwen die zijn 
gesteriliseerd met Essure®. Dit zijn metalen veertjes die via de 
baarmoeder in beide eileiders worden gebracht waardoor deze na 
ongeveer 3 maanden dichtgroeien. Het voordeel van deze 
sterilisatiemethode is, in vergelijking met de traditionele afsluiting van 
de eileiders, dat er geen chirurgische ingreep voor nodig is.  
Het aantal gemelde klachten komt van ruim 1,5 procent van de circa 
30.000 vrouwen die in Nederland met Essure® zijn behandeld. De meest 
genoemde klachten zijn pijn en vermoeidheid. Bij de pijnklachten gaat 
het vooral om de buik, de rug en het hoofd. Daarnaast worden hevige 
bloedingen tijdens en tussen de menstruatie, stemmingswisselingen, 
geheugenverlies en concentratieproblemen gemeld. Het werkelijke 
aantal vrouwen met klachten is onbekend.  
Veel vrouwen geven aan dat deze klachten hun dagelijks leven negatief 
beïnvloeden. Ze voelen de veertjes zitten of ervaren beperkingen bij het 
bewegen. Verder kunnen ze de dagelijkse taken en de zorg voor 
kinderen vaak minder goed uitvoeren. Er zijn ook vrouwen die aangeven 
dat hun relatie lijdt onder de ontstane problemen. Bij 16 procent van de 
vrouwen die klachten gemeld hebben, is Essure® verwijderd naar 
aanleiding van de klachten. 38 procent van de vrouwen in dit onderzoek 
heeft een afspraak gemaakt om dat te laten doen. 
De klachten zijn gemeld nadat hieraan via diverse kanalen aandacht is 
besteed. De Nederlandse Vereniging voor Obstetrie en Gynaecologie 
(NVOG) heeft de resultaten van de analyse medisch geduid. Sommige 
klachten zijn mogelijk toe te wijzen aan de plaatsing van Essure®, zoals 
bepaalde pijnklachten. Bij andere klachten is het moeilijker om een 
direct verband te leggen omdat er ook andere zaken van invloed kunnen 
zijn, zoals stoppen met de pil waardoor menstruatieklachten kunnen 
verergeren. Daarnaast komen verschillende klachten, bijvoorbeeld 
gewichtsschommelingen en urinewegproblemen, ook met enige 
regelmaat voor bij vrouwen die geen Essure® hebben. 
De gemelde klachten komen van vrouwen die tussen 2001 en 2016 het 
implantaat hebben gekregen. Hun gemiddelde leeftijd was 37 jaar op 
het moment van de sterilisatie.  
Kernwoorden: Essure®, hysteroscopisch, sterilisatie vrouw, implantaat, 
gezondheidsproblemen, klachten, bloeding, pijn, verwijderen 
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Synopsis 
Analysis of complaints in the Netherlands on Essure®
Health problems following a non-surgical sterilization procedure for 
women 
The RIVM has analyzed the complaints reported by women sterilized 
using Essure®. Essure® is a sterilization method where two metal coils 
are placed into both fallopian tubes through the cervix and uterus, 
provoking those to become blocked after approximately 3 months. In 
comparison with the traditional sterilization methods, the advantage of 
the Essure® method is that no surgical procedure is required. 
The complaints that were received came from more than1,5 percent of 
the 30.000 women who are estimated to have been sterilized using 
Essure® in the Netherlands. Probably not all women with health 
problems have submitted a complaint; therefore, the actual number of 
women with health problems is unknown. The most frequently 
mentioned health problems are pain and tiredness. The pain is reported 
to be located mainly in the abdomen, back, and head. In addition, heavy 
bleeding during and between menstruations, mood swings, memory loss 
and concentration problems are also reported frequently. 
Many women indicated that these health problems negatively affect their 
daily life. They feel the coils in their body and often experience 
limitations when moving. They are often less able to adequately perform 
their daily tasks and take care of their children.There are also women 
that indicated that their relationship was negatively affected by the 
health problems. In 16 percent of the women in this study, Essure® has 
been removed because of the health problems and 38 percent of the 
women have made an appointment to have Essure® removed. 
The complaints were submitted, among other reasons, because the 
media attention on problems experienced by women following 
sterilization using Essure®. The Dutch Society of Obstetrics and 
Gyneacology (NVOG) contributed to the interpretation of the results 
from this study. Some health problems can be directly related to 
Essure®, for instance some kinds of pain. For other health problems it is 
more difficult to establish a direct link, because other factors may 
influence the health problems as well.  For instance, heavier 
menstruation may also be explained by the fact that women stopped 
taking oral contraceptives following sterilization using 
Essure®.Furthermore, there are other health problems such as weight 
changes and urinary tract problems that are also regularly experienced 
by women not sterilized with Essure®. 
Women that submitted a complaint were sterilized using Essure between 
2001 and 2016. Their mean age at implantation was 37 years.  
Keywords: Essure®, hysteroscopic, female sterilization, implant, health 
problems, complaints, bleeding, pain, removal 
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Introduction 
1.1 General 
Female contraception can be achieved by non-permanent methods, like 
oral contraceptives and intra-uterine devices, or by permanent methods. 
Permanent sterilization can be accomplished by blocking the fallopian 
tubes via a laparoscopic and hysteroscopic sterilization. The sterilization 
methods described below are applied in the Netherlands.It is estimated 
that 10.000 women are sterilized in the Netherlands each year. There is 
no good registrationsystem for sterilizations in the Netherlands so exact 
data on sterilization is lacking [1]. 
1.1.1 Laparoscopic sterilization 
A laparoscopic sterilization is a surgical procedure in which two small 
incisions are made in the abdomen to insert a laparoscope (camera) in 
one of the incisions and the instruments for the sterilization itself in the 
other. Laparoscopic sterilization can be achieved via surgical, 
mechanical, or electrical methods (Table 1 and Appendix 1) [2-8]. These 
procedures require general anesthesia which might be a risk for the 
patient. Complications are rare after a laparoscopic sterilization (less 
than 1 in 1000). Women can experience shoulder pain (due to use of 
carbon dioxide), abdominal pain, blood loss (due to damage to the 
uterus) and a feeling of weakness (due to operation/anesthesia) after 
the procedure, whichis temporary. Also wound complications, an 
infection, fever and damage to the intestine/bladder can occur due to 
the laparoscopic sterilization [2,3]. Besides, surrounding organs (i.a. 
small intestine) can be burned during electrocoagulation. This risk is 
higher when using unipolar forceps compared to the use of bipolar 
forceps [3]. 
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Table 1: Comparison of laparoscopic and hysteroscopic sterilization [8] 
Laparoscopic Hysteroscopic 
(Essure®) 
Experience +/- 40 years 13-14 years 
General anesthesia Yes No 
Local anesthesia No Possibly 
Invasiveness Invasive Minimal-invasive 
Policlinic placement No Yes 
Immediate reliability Yes No 
Recovery period Several days One day 
Control after 3 months 
needed 
No Yes 
Risk of failure of the 
procedure 
Minimal +/- 5-10% 
Possible side effects - Infection 
- Blood loss 
- Abdominal 
pain 
- Shoulder pain 
- Damage 
intestine 
/bladder 
- Infection 
- Blood loss 
- Pain 
- Weight 
fluctuations 
- Mood swings 
- Skin irritation 
Pregnancies after 
successful procedure 
2-5/1000 0-4/1000 
1.1.2 Hysteroscopic sterilization 
Hysteroscopic sterilization is a non-surgical procedure that does not 
require general anesthesia. An implant is placed in the fallopian tubes 
via the cervix and uterus. Currently, Essure® is used for hysteroscopic 
sterilization. In addition, several new methods are being tested in trials 
(Altasea® and Ovalastic®) (Table 1, Appendix 1). 
Essure® implants, manufactured by Bayer (Essure® was originally 
developed by Conceptus Inc.. In 2014 Conceptus Inc. was acquired by 
Bayer), are coils which are inserted via the cervix and uterus into the 
fallopian tubes (Figure 1, Appendix 1). A device is used to deliver the 
implants into the fallopian tubes where the implant is expanded and 
anchors itself. This procedure usually takes less than 10 minutes [9]. 
After inserting the coils, connective tissue develops around the coils via 
a natural immune response, leading to a complete blockage of the 
fallopian tubes in approximately 3 months (Figure 1). A test is needed to 
confirm that the coils are correctly positioned and the fallopian tubes are 
indeed completely blocked, e.g. using a radiographic test called 
hysterosalpingogram (HSG), X-ray or ultrasound. 
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Figure 1: Essure method: A coil is inserted into the fallopian tubes via the cervix 
and uterus. Tissue develops around the coils, leading to a complete blockage of 
the fallopian tubes.  
 
1.1.3 Situation around Essure® in the Netherlands 
In the Netherlands, Essure® has been implanted in approximately 
30.000 women since 2002 [10,11]. Up until 2016, only a limited number 
(<1%) of women indicated that they experienced health problems after 
implantation of Essure®. Severe associated health problems sometimes 
led to the removal of the Essure® implants. The Landelijk Meldpunt Zorg 
(National Health Care Report Centre, LMZ) received complaints from 
women and forwarded those to the Dutch Health Care Inspectorate 
(IGZ). The complaints were related to the problems that women 
experienced during or after implantation. In the complaints, the health 
problems most often mentioned were back pain, abdominal pain, 
muscular pain, joint pain, bleeding, and tiredness. Other complaints 
mentioned broken implants and problems during implantation [12]. The 
LMZ also received complaints from women that indicated they had a 
nickel allergy. Currently, the manufacturer warns for a possible allergic 
reaction to nickel, but nickel allergy is not a contra-indication in Europe 
for sterilization using Essure®.  
In 2014, the IGZ noticed a slight increase in the number of complaints 
concerning Essure®. Therefore, the IGZ requested additional information 
from the manufacturer concerning the reports on incidents received 
worldwide, in Europe and in the Netherlands. Moreover, the IGZ 
contacted the Dutch Society of Obstetrics and Gynaecology (NVOG) to 
obtain information about the clinical experiences with Essure®.  
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On March 7, 2016, the Dutch TV program “Radar” was dedicated to the 
problems that women experienced with the Essure® sterilization 
method. In this program, women suffering from health problems 
following implantation of Essure® were interviewed. Following this 
program, IGZ published an appeal on their website dedicated to 
Essure®. The IGZ appealed women that experienced problems following 
Essure® placement to report their problems to LMZ. This website also 
indicated that RIVM was going to perform a study into the health 
problems reported to LMZ. 
 
1.2 Scope 
Following the appeal of the IGZ and the TV program, the IGZ requested 
the RIVM to perform a study into the complaints related to the Essure® 
sterilization treatment that women reported to the LMZ. This study 
included complaints reported to the LMZ both before and after (from 
March 7th 2016 until April 18th 2016) this appeal and the TV program 
Radar. 
 
Main question:  
Are there trends in the medical issues women experienced following 
Essure® sterilization? This general question was specified in the 
following sub-questions. 
 
Sub-questions:  
• Which health problems did women experience following Essure® 
sterilization?  
o Which problems did women experience following a 
procedure during which events occured? 
o Which problems did women experience following a 
procedure without events? 
• After what period of time following Essure® sterilization did the 
problems start? 
• What is the frequency of occurrence of the problems following 
Essure® sterilization? 
• For how many women, with health problems following Essure® 
sterilization, was a diagnostic examination performed and what 
were the outcomes of such examination? 
• How many women had their Essure® implants removed and what 
effect did this have on the problems that these women 
experienced? How were the Essure® implants removed (together 
with the fallopian tubes or also with the uterus)? 
• What influence did the health problems have on the daily life of 
these women (e.g. employment, sport, family life)?  
• How often are there other causes than the Essure® sterilization 
for developing the problems that were reported?  
o What are these other causes? 
• How many women who experienced health problems reported to 
have a nickel allergy?  
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2 Methods 
2.1 Received complaints 
Complaints received in two periods were included in this study, namely 
complaints reported following the appeal of the Dutch Health Care 
Inspectorate (IGZ) and the TV program of March 7th 2016 (March 7th 
until April 18th) and complaints which were submitted before this period. 
Complaints analyzed in this study were exclusively obtained from the 
LMZ. Women could contact the LMZ, either by submitting a web-based 
form or by telephone. After submission of a web-based form, LMZ 
contacted by telephone the person that submitted the form. The 
inclusion of submissions following the appeal of the IGZ and the TV 
program continued until the number of submissions returned to the level 
existing before the appeal following the TV program.  
A list with specific questions to be asked by LMZ was developed to 
obtain the information necessary to answer the sub-questions as far as 
possible. The completed complaints were a combination of the 
information initially submitted by the women and the information added 
by the workers of LMZ following the telephone contact with the women. 
IGZ received the complaints from LMZ and then forwarded them to the 
RIVM, if women agreed to have their complaint included in the RIVM-
study. 
 
2.2 Analysis of complaints 
The complaints were received as Word documents, containing the 
information received by LMZ. An MS Excel database was developed, 
where the information from the complaints on Essure® were entered 
anonymized. Health problems were classified into 7 different categories. 
Each complaint was evaluated individually and the answers were scored 
into the database. The variables included data on the health problems 
reported, the onset time of the problems and the actions taken by the 
women to solve their problems. The sub-questions to be answered were 
taken into consideration (see Appendix 2 for description of variables 
included). The data were analysed using the statistical analysis program 
SPSS (IBM, Armonk, USA). 
The results from anonymized complaints related to Essure®, which had 
been received before the TV program by the LMZ, were also included in 
this study. These complaints were not completed with a specific 
questionnaire and had not been analysed using the same database. A 
comparison could therefore only be made between the two sets of 
complaints on category level. 
The results of this study were discussed with the NVOG [13]. 
Observations from the NVOG on the results are included in this report. 
 
2.3 Literature search 
For remarkable findings, a limited search of the scientific literature was 
performed to check whether such findings had already been reported in 
the literature. For the literature search, “Essure” was used as the 
keyword in Pubmed. This search generated 222 results. First, the title of 
each article was reviewed and scored as applicable if it was expected 
that the article might describe events during the procedure and/or 
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health problems. Case reports were excluded. The abstracts from the 
selected articles were then evaluated. The relevant articles were used, 
which described the complications during placement and/or the health 
problems that developed after placement of the Essure® in a group of 
women. Another literature search (in Pubmed as well as Google) was 
performed to obtain information about sterilization methods other than 
the Essure® method. A literature search was also performed to obtain 
more information concerning nickel allergy and health problems related 
to other implants which contain metals. 
The main findings were also compared to the information, mainly 
warnings, precautions and contra-indications, stated in the 
manufacturer’s Instructions for Use (IFU version 1/07/2013 and 
11/11/2015), that was provided by the IGZ. 
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3 Results 
In total, the LMZ received approximately 500 complaints related to the 
Essure® implants. Over 400 complaints were received after the appeal of 
the IGZ and the TV program Radar. Not all women gave permission to 
use their complaints for this study and therefore 373 complaints 
received after the appeal and the TV-program were forwarded to the 
RIVM. The IGZ also received complaints before this period (referred to 
as “earlier complaints” from here onwards). In 372 of the 373 cases, 
these complaints included events during the procedure and/or the 
development of health problems. One woman reported a successful 
placement of the Essure® without the development of health problems. 
Less detailed information was obtained from the earlier complaints due 
to i.a. the lack of the specific questionnaire of the LMZ. The following 
tables and figures are therefore based on the 373 complaints received 
after the appeal of the IGZ and the TV program. 
 
The women who reported the complaints were born between 1961 and 
1988. The earliest Essure® implantation reported was in 2001 and the 
latest in 2016, while most placements took place in 2012 (Figure 2). The 
average age at the time of implantation was 37 years, with the youngest 
woman being 24 years old and the oldest 50 years. 
Figure 2: Year of Essure® placement 
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In the following paragraphs, the events during or directly following 
placement and health problems after placement as reported by the 
women are described. Since more than one event or health problem was 
often reported by one woman, the total number of events and health 
problems can be more than the total number of complaints and 
therefore more than 100%, as the percentages are calculated using the 
number of complaints.  
 
3.1 Events during Essure® implantation 
261 women (70%) reported that events occured during the placement 
(Table 2). 
 
Table 2: Events during Essure® placement 
Events during placement % of total 
(n=373) 
Events during procedure 70% 
(n=261) 
Painful placement 56% 
Other events 42% 
Nauseous or dizzy 8% 
Placement only on one side 6% 
Fallopian tube perforation 1,1% 
Breaking of implant 0,5% 
Other 31% 
 
A wide variety of events were reported. More than half of the women 
(56%) experienced pain during the placement. In 42% of the women 
other events occurred, like for instance nausea or dizziness (8%). In 
approximately 6% of the women the placement was so difficult that only 
one Essure® implant was placed and a second procedure was needed to 
achieve a complete sterilization. Nearly one third of the women (31%) 
reported events that were not listed as a separate option in the 
database and were therefore scored as ‘other’. ‘Other’ was often scored 
when it was only indicated that the placement was difficult without 
further description. It was not clarified in the complaints if the events 
were due to the experience of the gynecologist, the anatomy of the 
patient or to other causes. 
Comparing this to literature, two studies on Essure® (including a so-
called Phase II study) described that around 70% of the women 
experience pain during the placement [14,15]. In our study, this 
percentage was slightly lower (56%). On the contrary, a Phase III study 
(which is also used for the manufacturer’s IFU) described that 13% 
experienced pain during the placement and 30% experienced cramping 
[16]. This Phase III study also reported nausea as a postoperative 
symptom in 11% of the women, which is slightly higher than the 8% in 
our study [16]. 
 
Six women (~2%) reported events which were related to perforation of 
the fallopian tube or breaking of the implant. Given this low number, no 
reliable comparison could be made between the incidence and type of 
health problems experienced by women who had such events vs. those 
who had not. Moreover, reporting of these events might not be 
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accurate, since women might not always be aware of these type of 
events that occurred during placement. 
 
3.2 Onset time of health problems 
The onset time is the time between placement of the implant and the 
moment the health problem(s) started. In 232 complaints (62%), the 
general onset time when the first health problems appeared was 
mentioned. A wide variation (0-9 years) in onset time was observed 
(Figure 3, left histogram). On average, it took 7 months for the first 
health problems to appear. The health problems arose within the first 
month after placement in 40% of the women, and 90% of the women 
encountered problems within the first year. The onset time per type of 
health problem can be found in Appendix 3. 
 
 
Figure 3: Onset time (in months) of reported health problems. Whole range (left 
histogram) and detail of the first 24 months after placement of Essure® (right 
histogram). 
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3.3 Type of health problems following Essure® implantation  
The women that submitted a complaint reported a wide range of 
physical and psychological health problems. Therefore, the health 
problems were classified into categories. Most women experienced 
health problems related to pain (94%), psychological issues (91%) and 
bleedings (54%). In addition, allergy-related health problems (36%), 
gastro-intestinal/liver (27%) and kidney/urinary tract (23%) health 
problems were reported. Most women (90%) also reported a wide 
variety of health problems that were classified in a separate category 
“other problems” (Figure 4 and Appendix 4). 
 
Figure 4: Percentage of women experiencing each category of health problems 
following Essure® placement. 
 
The health problems and the trends thereof observed are comparable 
between the complaints received after the appeal of IGZ and the TV 
program and the earlier complaints, although the rates of occurrence 
differ.  
The NVOG recognizes most of the health problems, since they are often 
reported by women during policlinic visits [13]. 
 
3.3.1 Pain 
In total, 352 women (94%) experienced pain after the implantation of 
Essure® (Table 3). Abdominal pain was described most often (51%), 
followed by back pain (49%). Also pain in the head, pelvis/hips and legs 
were frequently mentioned. Additionally, 31% of the women 
experienced joint pain (arthralgia), whereas muscle pain, cramps and 
radiation to the legs were described by approximately 10% for each. 
Women also felt more pain during ovulation (23%), menstruation (16%) 
or coitus (13%).  
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Table 3: Pain related health problems following Essure® placement 
Health problem % of total 
(n=373) 
PAIN 94% 
(n=352) 
During ovulation 23% 
During menstruation 16% 
During coitus 13% 
  
Abdomen 51% 
(Lower)back 49% 
Head 31% 
Pelvis/hips 28% 
Legs 23% 
Groin 13% 
Breasts 9% 
Knees 3% 
Other location 22% 
  
Arthralgia 31% 
Muscle pain 13% 
Cramps 12% 
Radiating to legs 11% 
 
Eventhough pain is frequently reported in this study, pain is less 
commonly mentioned in the literature. A Phase III trial described pain 
during menstruation, coitus and ovulation in only 6%, 4% and 3% of the 
women, respectively [17]. This difference in occurrence rate might be 
explained by the different populations. Our study consist only of women 
who reported health problems, while a Phase III study contains women 
with and without health problems after the placement of the Essure® 
implants. 
 
According to the NVOG, gynecologists see perforations due to the 
Essure® or kinked coils once in a while during the confirmational check 
after 3 months, during diagnosis of the health problems, or during 
removal of the implants. This might induce pain-related health problems 
in for example the abdomen and the lower back [13]. On the other 
hand, a correlation is more difficult to find for more chronic pains, like 
arthralgia as stated by the NVOG. 
 
3.3.2 Psychological issues 
Most women (91%, n=338) experienced health problems classified in 
this study as psychological (Table 4). 70% reported tiredness, around 
40% reported mood swings or emotional imbalance, and around the 
same percentage reported memory loss or concentration problems. 
Approximately 20% of the women reported depressive feelings and an 
equivalent percentage of women experienced changes in body weight. 
Changes in body weight were in this study classified as “psychological 
problems”, although other causes are possible, including, but not limited 
to, hormonal changes.  
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Table 4: Psychological issues following Essure® placement 
Health problem % of total 
(n=373) 
PSYCHOLOGICAL COMPLAINTS 91% 
(n=338) 
Tiredness 70% 
Mood swings or emotionaly out of 
balance 40% 
Memory loss or concentration 
problems 39% 
Depressive feelings 21% 
Increase/decrease of weight 20% 
Insomnia 17% 
Loss of libido 15% 
Other 37% 
 
Remarkably, psychological issues are hardly mentioned in literature 
[16,17]. 
According to the NVOG, it is difficult to relate these problems to the 
Essure® implants since some of these mentioned health problems are 
common among women of the same age in the overall population (e.g. 
change in weight). The NVOG also indicated that a combination of some 
of these symptoms are seen as well in other diseases like Lyme disease 
and chronic fatigue syndrome [13]. Based on the assumption that older 
women may be more likely to experience these kind of psychological 
problems, we investigated whether there were age differences between 
women reporting psychological problems vs the overall population of 
women in this study or women not reporting psychological problems. 
This comparison was only done for those women reporting both 
psychological problems and the onset time of those problems. Based on 
the available data, there was no clear age difference between these 
groups of women (Appendix 5). 
 
3.3.3 Bleeding 
201 women (54%) reported health problems related to bleeding (Table 
5). These problems consisted of increased or heavy blood loss during 
menstruation (37%), irregular bleeding/breakthrough bleedings (20%) 
and blood loss during coitus (5%). 
 
Table 5: Bleeding problems following Essure® placement 
Health problem % of total 
(n=373) 
BLEEDING 54% 
(n=201) 
Increase or heavy blood loss during 
menstruation 37% 
Irregular bleeding or breakthrough 
bleeding 20% 
Blood loss during coitus 5% 
 
In a Phase III study, 38% of the women reported a recurrent heavier 
menstrual flow [17]. This is in the same range as our findings (37%). In 
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the same study, an irregular menstruation was experienced by 15% of 
the women and bleedings between menstruations by 19% [17]. Our 
study revealed irregular menstruation and/or breakthrough bleedings in 
20% of the women. These data are difficult to compare since we 
combined both health problems in one category and the population in 
these two groups is different since a Phase III study is a prospective 
cohort study and the current study contains only women with health 
problems after placement of the Essure® implants. 
According to the NVOG, increased or heavier blood loss during 
menstruation does not have to be related to the Essure® implants but 
can be related to the fact that women stop using oral contraceptives or 
Mirena® after confirmation of the sterilization. Women often start with 
these methods of birth control as a treatment for bleeding problems, 
since these methods might reduce blood loss by 30% as specified by the 
NVOG [13]. When stopping any of these treatments after confirmation 
of complete sterilization with Essure®, the menstrual flow can become 
heavier again. It is not explicitly asked in this study whether women 
used birth control before Essure® placement and if this treatment was 
stopped after confirmation of the sterilization. Additionally, some women 
had children, which may be another cause of heavier menstrual flow, 
since menstrual flow often changes after giving birth. Also 
bleedingdisorders may occur during perimenopause [13]. 
Moreover, breakthrough bleedings can be caused by perforation due to 
Essure® [13].  
 
3.3.4 Allergy-related health problems 
Allergy-related health problems were reported by 36% (n=133) of the 
women (Table 6). Itchy skin (16%) was the most frequent problem, 
followed by problems in the eyes (e.g. red or thick eyes, 10%), rash 
(8%) and eczema (6%). Although all women reporting eczema could be 
expected to report itchy skin as well, this was not always the case; 
therefore, the two types of health problems were kept separate. 
 
Table 6: Allergy-related health problems following Essure® placement 
Health problem % of total 
(n=373) 
ALLERGIES 36% 
(n=133) 
Itching skin 16% 
Allergic complaints in eyes (e.g. red, dry 
or thick eyes) 10% 
Rash 8% 
Eczema 6% 
Other 3% 
 
Some allergy-related health problems might be due to a nickel allergy. 
Essure® implants contain nickel, which might result in problems after 
placement if patients are allergic to nickel. In our study, 19% (n=71) of 
the women reported to have a nickel allergy and 9% (n=35) suspected 
to be allergic to nickel (e.g. they reported to only tolerate gold or silver). 
In Europe, around 20% of the population has a nickel allergy, with only 
a limited variation between countries. The prevalence of a nickel allergy 
is slightly higher in women compared to men [18-20]. Therefore, the 
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percentage of women in this study with a nickel allergy falls in the same 
range as the average of the European population (including men and 
women). 
Results from this study show that half of the women who reported to 
have a confirmed or suspected nickel allergy experienced allergy-related 
problems while the other half did not. On the contrary, only 30% of the 
women without nickel allergy experienced allergy-related problems 
(Table 7). It is not known how many women with a nickel allergy do not 
develop health problems. Therefore it is not possible to conclude that 
having a nickel allergy is related to a higher chance of experiencing 
allergy-related problems after placing of Essure®. But it can be 
concluded that women who experience allergy-related problems more 
frequently have a nickel allergy compared to women who do not suffer 
from allergy-related problems. 
 
Table 7: Percentage of allergy-related problems in women with, without or with 
a suspected nickel allergy.  
    Allergy-related problems 
    No Yes 
Nickel allergy 
No (n=267) 70% 30% 
Suspected (n=35) 51% 49% 
Yes (n=71) 48% 52% 
 
The 2013 and 2015  versions of the IFUstate: “Persons allergic to nickel-
titanium may suffer an allergic reaction to the micro-insert”. In the 
English section of the IFU for the US-only, a more elaborate statement is 
given: “The Essure micro-insert includes nickel-titanium alloy, which is 
generally considered safe. However, in vitro testing has demonstrated 
that nickel is released from this device. Patients who are allergic to 
nickel may have an allergic reaction to this device, especially those with 
a history of metal allergies. In addition, some patients may develop an 
allergy to nickel if this device is implanted. Typical allergy symptoms 
reported for this device include rash, pruritus, and hives.” 
In none of the current IFUs a nickel allergy is described as a contra 
indication. 
 
Allergy to metal in implants is well known for orthopaedic implants. For 
orthopaedic implants, sensitivity to chromium, cobalt and nickel has 
been observed. Stainless steel in orthopaedic implants can contain 
approximately 10% nickel [21]. Problems that are considered to be 
related to metal allergy for orthopaedic implants are eczema, swelling, 
delayed wound healing, pain and even implant loosening [22,23].  
In the Australian registry, “metal sensitivity” is indicated for 
approximately 6% of the revision surgeries for hip implants and 1% for 
shoulder implants [22,24]. An enquiry among German orthopaedic 
surgeons indicated that complications related to allergy are rare [25]. It 
is also indicated that, although metal sensitivity may develop, only 1% 
of the arthroplasty patients exhibit symptoms.  
The need and method used for the diagnosis of a nickel allergy before 
the placement of orthopaedic implants is debated. The usual patch skin 
test does not always indicate nickel allergy, whereas the lymphocyte 
transformation test (LTT) is considered more accurate, but more 
complex to perform [22]. It has been established that the frequency of 
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occurrence of metal sensitivity decreases with increasing age. The 
frequency of metal sensitivity among women under 40 years of age is 
estimated to be 23 %, whereas this drops to 1% for the age group over 
60 years [25]. 
The occurrence of allergy-related problems after implanting orthopaedic 
implants cannot be considered to be similar to the occurrence after 
placing Essure®. Orthopaedic implants, like hip and knee replacements, 
have a considerably higher weight than the Essure® coils and abrasive 
wear will lead to small particles being generated. This debris can lead to 
allergic and other reactions. The inner coil of Essure® is made of 
stainless steel and PET-fibers. The outer coil is made of nitinol, which is 
an alloy of titanium and nickel [26], and therefore, nickel will be in 
contact with the tissue of the patient. It is unknown how quickly nickel 
reacts or is released from the coil.  
As there is still uncertainty about the mechanisms of allergy-related 
problems for orthopaedic implants and there is also no clear mechanism 
for allergy related problems for Essure®, it cannot be established what 
types of problems of the Essure® coils can be attributed to nickel 
allergy. In literature, metal allergy and its consequences are mainly 
studied for orthopaedic implants, and not for implants used in the uterus 
or fallopian tubes. 
 
According to the NVOG, it is difficult to confirm that an allergy-related 
problem is caused by a nickel allergy or an a-specific inflammation. A 
nickel allergy is not included as a contraindication in the NVOGs 
guideline for sterilization [27]. Gynecologists in the Netherlands are 
currently investigating the application of Essure® in women with a nickel 
allergy. A conclusion cannot be drawn at this moment since this study is 
not completed yet. Despite the fact that there is no causal relation 
demonstrated between a nickel allergy and allergy-related problems, 
gynecologists warn their patients that there is a low chance of allergic 
problems if they have a nickel allergy. 
 
3.3.5 Gastro-intestinal or liver health problems 
Approximately one fourth of the women (n=99) experienced health 
problems related to the gastro-intestinal tract or liver. These health 
problems were often not described in detail in the reported complaint 
but, when specified, they were mainly: altered stool (constipation or thin 
stool), strange taste, and bile problems. 
The NVOG does not recognize all these health problems in relation to 
Essure®. For example, a strange taste is not frequently mentioned by 
their patients and cannot be explained by the NVOG.  
 
3.3.6 Kidney and urinary tract health problems 
From the women who experienced kidney and urinary tract problems 
(23%, n=86), problems related to urinating (less/often or difficult, 9%), 
bladder infection (7%), and incontinence (7%) were reported most 
frequently (Table 8).  
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Table 8: Kidney and urinary tract health problems following Essure® placement 
Health problem % of total 
(n=373) 
KIDNEY AND URINARY TRACT COMPLAINTS 23% 
(n=86) 
Problems with urinating (often/less, difficult) 9% 
Bladder infection 7% 
Incontinence 7% 
Other 1% 
 
For some health problems, such as a bladder infection and pain during 
urinating, the relation with the Essure® implants is considered limited by 
the NVOG, as these type of problems are common in the Dutch 
population. Women come to the outpatient clinic with these problems on 
a daily basis [13]. 
 
3.3.7 Other health problems 
Besides the health problems classified in the categories above, 90% of 
the women (n=334) deal with other problems ranging from a tingling 
feeling in e.g. limbs (20%) to excessive sweating (18%) and swollen 
abdomen (17%) (Table 9). It is unknown if there is a realtion between 
these health problems and the Essure® implants. 
 
Table 9: Other type of health problems following Essure® placement 
Health problem % of total 
(n=373) 
OTHER COMPLAINTS 90% 
(n=334) 
Tingling (hands, feets, legs and arms) 20% 
Excessive sweating 18% 
Swollen abdomen 17% 
Menopause complaints 16% 
Hair problems (e.g. hairloss) 14% 
Arrhythmia 11% 
Vaginal secretion (e.g. much secretion) 11% 
Fungal infections (vaginal or other) 11% 
Vision problems 11% 
Feeling the implant 9% 
Other 27% 
 
3.4 Influence on daily life 
The health problems experienced by the women in this study often have 
a considerable impact on their daily life. Three-quarter (75%, n=280) of 
the women reported that the health problems that developed after the 
placement of Essure® had an impact on their daily lives in one or more 
ways (Table 10), while 25% of the women did not provide any 
information on this question. A large number of women encountered 
problems related to work (39%), ranging from having difficulties with 
certain tasks, e.g. standing for a prolonged period of time, to not being 
able to work at all. One third of the women experienced a major impact 
on their relationship and/or family life. There are, for example, women 
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who describe that they cannot participate in activities with their children 
anymore or who were recently divorced, in which their health problems 
played a role. Most likely, health problems like pain and tiredness are 
considered to contribute to a large extend of the problems they 
encounter in their daily life.  
 
Table 10: Overview of influence on daily life 
Influence on daily life % of total 
(n=373) 
Influence on daily life 75% 
(n=280) 
Work-related problems 39% 
Relation and/or family problems 34% 
Problems with daily tasks (e.g. at home) 24% 
Mobility problems (e.g. during walking, biking, sports etc) 22% 
Lack of social activities and happiness (incl burnout) 9% 
Other 29% 
Influence not mentioned 25% 
 
3.5 Visiting doctor/specialist and diagnosis 
Around 90% (n=335) of the women visited a doctor for their health 
problems (Appendix 6) and 21% explicitly mentioned to have visited a 
gynecologist. 53% of the women who reported their problems have 
undergone some kind of diagnostic testing such as control of the 
position of Essure® (9% of the women), blood test (22%) or a wide 
variety of other tests (37%) like MRI or echo (without further specifying 
if this was done to control the position of the implant or for another 
medical reason). From those women who mentioned the outcome of the 
tests, half of them received a diagnosis while in the other half nothing 
was found. It was not clarified if the diagnosis was related to the 
Essure® or not. 
In a fair number of cases, the complaints indicated that visits to the 
doctor were mainly related to the occurrence of health problems and 
treatment or diagnosis thereof, and not directly related to problems with 
the implants. Therefore, no direct relationship between visiting doctors 
and undergoing examinations and Essure® could be established. It is 
difficult (for the physicians) to link the health problems that women 
experienced to the implants due to the type of problems that the women 
report, since the reported health problems are common and can be 
related to a lot of other causes. 
 
Perforation of i.a. fallopian tube after the placement of the Essure® 
implants was reported by 10 women (3%). In 4 of them, perforation 
was recognized during placement of Essure® while in the other 6, 
perforation was only revealed later after doctor’s examination. This 
percentage is difficult to compare with literature since a wide variety of 
percentages are described in literature. Al-Safi et al evaluated the 
Essure® complaints of women in the FDA’s Manufacturer and User 
Facility Device Experience (MAUDE) database [27]. This is a database in 
which patients as well as manufacturers, health professional and 
healthcare centres can submit complaints on all kind of devices. Since 
multiple persons can submit complaints in this database it is possible 
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that one event is reported several times (e.g. by a patient and a 
doctor). For Essure®, perforation was described in 20% of the events in 
the MAUDE database. On the contrary, a Phase II and Phase III study 
report a perforation rate of 3% and 1% respectively [15,16]. This 
variation in occurrence rate might be explained by the different 
populations. The MAUDE database consist only of women who reported 
health problems, while a Phase II/III study contains women with and 
without health problems after the placement of the Essure® 
implants.The NVOG mentioned that they observe perforations after 
placement of the Essure® once in a while. Therefore, perforation might 
be underreported in our study. This underreporting of perforations may 
be due to the fact that this was not asked literally in the questionnaire 
used by the LMZ and women might often not remember this event.  
 
3.6 Removal of Essure® 
The Essure® implants were removed in 16% (n=60) of the women 
(Table 11). Of these women, 53 indicated that a single or both the 
fallopian tubes were removed together with the Essure®. Since the 
Essure® implants become fully embedded in tissue that develops in the 
fallopian tube after insertion, it is difficult to remove the Essure® 
implants while maintaining the fallopian tubes intact. Therefore, it is 
expected that the fallopian tubes are removed in 100% of the women. 
The uterus was removed together with the fallopian tubes in a quarter of 
the women, and the ovary was removed in two women. The implants 
were removed between 2010 and 2016, on average 4 years after 
placement, ranging from two weeks to over 13 years after placement 
(Figure 5). 
 
From the women who had the implants removed, 23% (n=14) reported 
to be fully recovered after the removal while 48% (n=29) is still 
recovering. One out of 10 women did not notice any improvement/relief 
of their health problems after the removal. From 18% (n=11) of the 
women it is unknown if they recovered after the removal of the 
implants. There was a slightly different prevalence of health problems 
before removal of Essure® among the women who recovered vs women 
who did not recover after the removal (Appendix 7). For instance, 51% 
(n=18) of women who did not recover reported allergy-related problems 
before removal, while none of the women in the group that recovered 
did. It is hard to interpret this data. This may indicate that allergy-
related problems are, at least in the short term, not solved by removal 
of Essure®. It might also be possible that women with a nickel allergy 
are more aware of allergy-related problems and link this quicker to the 
Essure® implants. Besides, small particles might still be present after 
removal of the Essure® implants or the allergy-related problems might 
have another cause than the implants and therefore the health problems 
remain afer removal of the implants. 
On the contrary, bleeding before removal was more prevalent in the 
group of women that recovered vs the other group. However, results 
from such a descriptive analysis should be interpreted with caution. 
 
At the time of reporting to LMZ, 38% (n=140) of the women with health 
problems had an appointment planned for the removal of the Essure® 
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implants and 8% (n=31) explicitly mentioned they were considering the 
removal of the implants. 
 
Table 11: Removal of Essure® and outcome after removal 
  % of total (n=373) 
Essure removed 16% 
One follopian tube removed 1% 
Two follopian tubes removed 13% 
Uterus removed 4% 
Ovary removed 1% 
Removal Essure planned 38% 
Removal Essure considered 8% 
Removal not mentioned 38% 
  
  % of removed (n=60) 
Recovered after removal Essure 23% 
Still recovering after removal Essure 48% 
Not recovered after removal Essure 10% 
Unknown 18% 
  
  
Time after which Essure was 
removed (months) 
Mean 49 
Standard deviation 35 
Minimum 0,5 
Maximum 157 
 
 
Figure 5: Time (years) elapsed between placement and removal of Essure® 
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4 Discussion and conclusions 
4.1 Discussion 
4.1.1 General/method 
In the Netherlands, there are approximately 30.000 women sterilized by 
the Essure® method. In this investigation, data were extracted from 373 
complaints submitted to the LMZ related to problems with the Essure®. 
The number of health problems can be assumed to be higher in the total 
population of Essure® users since it is not expected that all women 
experiencing health problems have reported this to LMZ. On the other 
hand, by far, most women do not report health problems after the 
Essure® treatment. Lastly, the NVOG notified that the Dutch Facebook 
page for Essure® problems advised women to report as many health 
problems as possible so that the chance that gynecologists would 
remove the implants would be higher. This might have some influence 
on the data from this study. Eventhough women often indicate that they 
want the Essure® implants removed it should be noted that the removal 
is a complex procedure and it is not guaranteed that the Essure® will be 
completely removed (sometimes small particles remain) or that the 
health problems resolve. 
 
4.1.2 Implementation of the Essure® method 
According to the NVOG, the Essure® sterilization method has been 
implemented gradually in the Netherlands. Gynecologists first received 
training and their performance had to be observed before they were 
allowed to apply this method independently. In the Netherlands, 
gynecologists were trained to assess HSG and X-ray pictures and to 
recognize perforations. In addition, there is a panel of experts that can 
be consulted in case of complications or e.g. doubts about X-ray 
pictures. 
In the USA, the Essure® method was implemented differently compared 
to the Netherlands, according to the NVOG [13]. Al-Safi et al, evaluated 
the complaints about Essure® in the MAUDE database (a USA based 
database). 20% of the complaints in the MAUDE database were related 
to perforations [27]. On the contrary, the perforation rate was around 
2% in Phase II and III studies which were also (partially) conducted in 
the USA [15,16] but presumably in a more controlled setting. Thirteen 
percent of the complaints in the MAUDE database described unintended 
pregnancies, while this was only reported by 1 woman (0.3%) in our 
study. The Phase II and III studies did not observe any unintended 
pregnancies. 
 
4.1.3 Association between Essure® and health problems 
The RIVM discussed the results with the NVOG and IGZ to evaluate 
which health problems could be related to the Essure® implants. The 
NVOG indicated that breakthrough bleedings and pain-related problems, 
especially in the abdomen and lower back, could be linked to the 
Essure® implants. A heavier menstrual flow, instead, was most likely 
caused by stopping with the contraceptive pill after a confirmed 
sterilization, as contraceptive pills are known to reduce blood loss during 
menstruation. In addition, some health problems like pain during 
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urinating and weight changes are common in women and are therefore 
not likely to be linked to the Essure®. It is difficult to determine the 
relationship between Essure® and the more general health problems 
reported. Besides, the health problems sometimes develop after a long 
period. Due to the long onset time, it is difficult to determine whether 
these health problems are related to Essure® or not. For example, one 
woman reported that the first health problems appeared after 9 years. 
Currently, the NVOG investigates if the health problems resolve after the 
removal of the Essure® implants to give insight into the relation between 
Essure® implants and the health problems. 
Some gynecologists observed a layer of sediment on the metal coils  
during the removal of the implants, according to the NVOG. Currently, 
gynecologists investigate why this sediment forms and what is the 
possible consequence. The time span after which this sediment is 
formed is still unknown. Although the formation of this sediment might 
be a cause of some of the health problems, it is not likely to explain all 
the health problems observed in this study. 
The influence of a nickel allergy on the development of health problems 
is also unknown. Overall, more research would be needed to establish a 
causal relationship between Essure® and the reported health problems 
including the effects of a nickel allergy. Also the likelihood to recover 
after removal of the implants should be investigated.  
 
4.1.4 Position NVOG about Essure® 
The NVOG does not see a reason to be negative regarding Essure® as a 
sterilization method despite the fact that some women report health 
problems after its placement. For some women, the Essure® method is a 
better choice compared to other, more conventional sterilization 
methods that also bring along some risks. For example, the Essure® 
sterilization method is less risky compared to invasive methods for 
women who had multiple operations in the abdominal area. In addition, 
most women do not experience health problems after the placement of 
Essure®. A case-by-case weighing of the risks and benefits of Essure® 
compared to alternative methods should be done. In addition, the NVOG 
considers it important to inform their patients adequately about the 
possible health problems after placement of the Essure® implants. The 
NVOG suggests that more extensive studies (e.g. randomized clinical 
trials) are needed when new products are used in a large population. 
 
4.2 Conclusions 
Complaints were received from approximately 500 women who were 
sterilized with Essure® implants. This corresponds to more than 1.5% of 
the total amount of women sterilized with Essure® in the Netherlands. A 
wide variety of health problems were reported. The average reported 
onset time of health problems was 7 months, ranging between 0 and 
108 months. The most frequently reported health problems were pain 
(94%), psychological issues (91%) and deviant bleedings (54%). In our 
study population, there was a slightly higher frequency of allergy-related 
problems in women who reported to be allergic to nickel compared to 
women without this allergy. In approximately three quarters of the 
women, the health problems had a considerable influence on the 
women’s daily life, mainly related to work, family/relationship and daily 
duties. The Essure® implants were removed in 16% of the women, with 
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almost one quarter of these women recovering from their health 
problems after the removal. 38% of the women have planned to have 
Essure® removed. 
For some of the health problems (e.g. abdominal pain and breakthrough 
bleeding) there could be a possible relationship with the Essure®; for 
other health problems (e.g. weight changes and urinary tract problems), 
this link is less likely.  
Eventhough some women experience health problems after the 
placement of Essure®, this method might be beneficial for some women 
since no general anesthesia and operations are needed which is the case 
for laparoscopic sterilization. There is no long term study conducted into 
the relation between the Essure® implants and the development of 
health problems. This study indicates that there is a trend in health 
problems which the women experience after the placement of the 
implants but based on the available data it is not possible to determine 
if there is a causal relation between the health problems and the 
Essure® implants. 
  
RIVM Letter report 2016-0061 
Page 34 of 57 
 
RIVM Letter report 2016-0061 
Page 35 of 57 
5 References 
[1] Richtlijn Sterilisatie van de vrouw, Nederlandse Vereniging voor 
Obstetrie en Gyneacologie (NVOG), 2012 
 
[2] Sterilisatie van de vrouw per laparoscoop, 
Patientenvoorlichtingsfolder, Nederlandse Vereniging voor Obstetrie en 
Gyneacologie (NVOG) 
 
[3] Lawrie T.A. et al, Techniques for the interruption of tubal patency for 
female sterilisation. Cochrane Database Syst Rev. 2015 Sep 7;(9) 
 
[4] ESHRE Capri Workshop Group et al, Family planning 2011: better 
use of existing methods, new strategies and more informed choices for 
female contraception. Hum Reprod Update. 2012 Nov-Dec;18(6):670-81 
 
[5] Lawrie T.A. et al, Techniques for the interruption of tubal patency for 
female sterilisation. Cochrane Database Syst Rev. 2011 Feb 16;(2) 
 
[6] http://www.altascience.ie/ (visited on 22-08-2016)  
 
[7] http://www.urogynbv.com/behandeling/sterilisatie/ (visited on 22-
08-2016) 
 
[8] NVOG Voorlichtingsbrochure Sterilisatie, Nederlandse Vereniging 
voor Obstetrie en Gyneacologie (NVOG), 2015 
 
[9] Levie M. et al, A comparison of novice and experienced physicians 
performing hysteroscopic sterilization: an analysis of an FDA-mandated 
trial. Fertil Steril. 2011 Sep;96(3):643-648.e1 
 
[10] Hitzerd E. et al, Twelve-year retrospective review of unintended 
pregnancies after Essure sterilisation in the Netherlands. Fertil Steril. 
2016;105(4):932-7 
 
[11] http://www.medischcontact.nl/archief-
6/Tijdschriftartikel/152943/Gynaecologen-bezorgd-over-
Essuresterilisatie.htm?utm_source=subscribers_medischcontact_dagelijk
s&utm_medium=email&utm_term=&utm_content=&utm_campaign=20
160301 (visited on 19-05-2016) 
 
[12] http://www.igz.nl/onderwerpen/medische-technologie/actuele-
onderwerpen/essure/ (visited on 19-05-2016) 
 
[13] Meeting RIVM, IGZ and NVOG on 02-06-2016 
 
[14] Duffy S. et al, Female sterilisation: a cohort controlled comparative 
study of ESSURE versus laparoscopic sterilisation. BJOG. 
2005;112(11):1522-8 
 
RIVM Letter report 2016-0061 
Page 36 of 57 
[15] Kerin J.F. et al, Hysteroscopic sterilization using a micro-insert 
device: results of a multicentre Phase II study. Hum Reprod. 
2003;18(6):1223-30. 
 
[16] Cooper J.M. et al, Microinsert nonincisional hysteroscopic 
sterilization. Obstet Gynecol. 2003;102(1):59-67. 
 
[17] Chudnoff S.G. et al, Hysteroscopic Essure Inserts for Permanent 
Contraception: Extended Follow-Up Results of a Phase III Multicenter 
International Study. J Minim Invasive Gynecol. 2015 ;22(6):951-60 
 
[18] Uter W. et al, The European baseline series in 10 European 
Countries, 2005/2006--results of the European Surveillance System on 
Contact Allergies (ESSCA). Contact Dermatitis. 2009;61(1):31-8 
 
[19] Schmidt M. et al, Immunology of metal allergies. J Dtsch Dermatol 
Ges. 2015;13(7):653-60 
 
[20] Diepgen T.L. et al, Prevalence of contact allergy in the general 
population in different European regions. Br J Dermatol. 
2016;174(2):319-29 
 
[21] Thomas P. et al, Influence of surface coating on metal ion release: 
evaluation in patients with metal allergy. Orthopedics. 2016;39(3 
Suppl):S24-30 
 
[22] Hartmann D. et al, Metal implant sensitivity: clinical and 
histological presentation. Hautarzt. 2016;67(5):373-9 
 
[23] Guenther D. et al, Allergic reactions in arthroplasty: myth or 
serious problem? Int Orthop. 2016;40(2):239-44 
 
[24] Thomas P., Metal implant allergy update. Hautarzt. 
2016;67(5):343-6. 
 
[25] Thomsen M. et al, Use of allergy implants in Germany: results of a 
survey. Orthopade. 2013;42(8):597-601 
 
[26]Essure Instruction for Use (IFU), Bayer, version 2013 and 2015 
 
[27] Al-Safi Z.A. et al, Analysis of adverse events with Essure 
hysteroscopic sterilization reported to the Manufacturer and User Facility 
Device Experience database. J Minim Invasive Gynecol. 
2013;20(6):825-9 
  
RIVM Letter report 2016-0061 
Page 37 of 57 
Appendix 1: Overview of sterilization methods for women 
available in the Netherlands 
Laparoscopic sterilization (surgical) [3-7] 
Surgical methods  
Tubectomy Surgical removal of the fallopian tube 
  
A variant of the three methods below can be applied during a caesarian 
operation 
Pomeroy A chromic tie is placed around a loop of the 
fallopian tube after which 1-2 cm is excised. 
Irving method A segment between 2 ties is resected. 
Afterwards, one end is attached to the back of 
the uterus and the other end is buried in the 
surrounding connective tissue. 
Uchida method A vasoconstrictive solution is injected in the 
tubal mucosa. A part of the sub-serosa is 
dissected and 2 cm of muscular part is 
resected. One end retracts in connective 
tissue and the other end is exteriorized to 
peritoneal cavity. 
 
Mechanical methods  
Bands/rings A ring is placed around a loop of the fallopian 
tube. The ring contracts after release and 
closes the tube. The loop undergoes necrosis 
and separates from the healthy part of the 
tube. 
Hinged clips A clip is compressed around the fallopian 
tube. Only a small part of the tube is 
damaged. 
 
Electrical methods  
Electrocoagulation with 
bipolar forceps 
The fallopian tube is grasped by 2 forceps 
through which a current passes, which 
damages at least 3 cm of the tube. 
Hysteroscopic sterilization (non-surgical) 
Essure® implants A coil is inserted into the fallopian tube. The 
tube is blocked due to tissue growth around 
the coils. 
Altaseal® implants A stainless steel implant is placed in the  
fallopian tube and closes the tube immediately 
(Currently only applied in clinical trial) 
Ovalastic® implants A flexible rubber implant is placed in the  
fallopian tube and closes the tube immediately 
(Currently only applied in clinical trial) 
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Appendix 2: Description of the variables in the database 
Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
Administrative 
data  ADM_ Notification number ADM_NR_NOTIFICATION numeric 
1 up to last 
notification 
  
 
Follow up number LMZ ADM_LMZ_NR numeric 8 digit code 
  
 
Registrator REGISTRATOR string text (initials) 
  
 
Date of notification ADM_DATE_NOTIFICATION numeric format DD/MM/YYYY 
  
 
Date of birth  ADM_DATE _OF_BIRTH numeric format DD/MM/YYYY 
  
 
Date of Essure placement ADM_DATE_ESSURE numeric 
format DD/MM/YYYY  
- if there are 
multiple dates (e.g. 
between 2013-
2014), take the 
average  
- if only the month 
is mentioned, take 
the 15th as the date  
- start of 2016 = 
01-02-2016 
  
 
Age of woman when Essure was placed ADM_AGE_ESSURE numeric in years 
   In which hospital was the Essure placed? ADM_HOSPITAL string text  
How did the 
procedure go PROC_ How long did the placement take? PROC_TIME numeric in minutes 
  
 
Was the placement painful? PROC_PAIN numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
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Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
  
 
If so, how long did it last? PROC_PAIN_TIME numeric in days 
  
 
Where there any other complications? PROC_OTH_COMPLICATION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
If so, fallopian tube perforated? PROC_OTH_COMPLICATION_PERFORATION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
If so, adhesion? PROC_OTH_COMPLICATION_ADHESION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
If so, breaking of implant? PROC_OTH_COMPLICATION_BREAK numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
If so, placement on one side only? PROC_OTH_COMPLICATION_ONESIDE numeric 
1 (=YES), 0 (=NO), 
blank (= unknown), 
Second placement 
can be added at 
PROC_TREAT_AND 
  
 
If so, other? PROC_OTH_COMPLICATION_OTH numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
If so, nauseous and/or dizzy? PROC_COMPLICATION_NAUSEOUS_DIZZY numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
If other, which ones? PROC_OTH_COMPLICATION_OTH_TXT string text  
  
 
Treatment after procedure with complications       
  
 
Sterilisation with other methods PROC_TREAT_OTH_STERILIZATION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Novasure treatment PROC_TREAT_NOVASURE numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Other? PROC_TREAT_OTH numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
If other, which ones? PROC_TREAT_OTH_TXT string text  
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Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
    Result after procedure with complications PROC_RESULT string text  
Complaints COMP_ 
Time till start of complaints (if not specified per 
individual complaint) COMP_TIME numeric 
in months (or blank 
if unknown) 
  
 
Allergic complaints COMP_ALLERGIC numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Latency time COMP_ALLERGIC_TIME numeric 
in months (or blank 
if unknown) 
  
 
Allergy for products (e.g. shampoos, parfume) COMP_ALLERGIC_PRODUCTS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Eczema COMP_ALLERGIC_ECZEMA numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Rash COMP_ALLERGIC_RASH numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Itching skin COMP_ALLERGIC_ITCHING numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Allergic complaints in eyes (e.g. red, dry or thick 
eyes) COMP_ALLERGIC_EYES numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Urticaria COMP_ALLERGIC_URTICARIA numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Bleeding COMP_BLEED numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Latency time COMP_BLEED_TIME numeric 
in months (or blank 
if unknown) 
  
 
Increase or heavy blood loss during menstruation COMP_BLEED_MENST numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Irregular bleeding or breakthrough bleeding COMP_BLEED_IRREGULAR numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Blood loss during coitus COMP_BLEED_COITUS numeric 1 (=YES), 0 (=NO), 
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Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
blank (= unknown) 
  
 
Location COMP_BLEED_LOCATION string text  
  
 
How often (interval between two bleeding 
episodes) COMP_BLEED_INTERVAL numeric 
in days (or blank if 
unknown) 
  
 
Duration of bleeding COMP_BLEED_DURATION numeric 
in days (or blank if 
unknown) 
  
 
Gastro-intestinal or liver complaints COMP_GI numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Latency time COMP_GI_TIME numeric 
in months (or blank 
if unknown) 
  
 
Thin stools COMP_GI_THIN_STOOL numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Bile problems COMP_GI_BILE numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Liver problems COMP_GI_LIVER numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Constipation COMP_GI_OBSTIPATION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Strange taste in mouth (e.g. metal taste) COMP_GI_TASTE numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Smelly breath COMP_GI_SMELLY_BREATH numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Kidney and urinary tract COMP_KIDNEY_URINE numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Latency time COMP_KIDNEY_URINE_TIME string 
in months (or blank 
if unknown) 
  
 
Adrenal exhaustion 
COMP_KIDNEY_URINE_ADRENAL 
EXHAUSTION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
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Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
  
 
Bladder infection COMP_KIDNEY_URINE_BLADDER_INFECTION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Dark urine COMP_KIDNEY_URINE_COLOUR numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Incontinence COMP_KIDNEY_URINE_INCONTINENCE numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Problems with urinating (often/less, difficult) COMP_KIDNEY_URINE_URINATE numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Pain related complaints COMP_PAIN numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Latency time COMP_PAIN_TIME string 
in months (or blank 
if unknown) 
  
 
When was the pain worse?       
  
 
During ovulation COMP_PAIN_OVULATION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
During menstruation COMP_PAIN_MENSTRUATION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
During coitus COMP_PAIN_COITUS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Location       
  
 
Pelvis/hips COMP_PAIN_HIPS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Legs COMP_PAIN_LEGS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Abdomen COMP_PAIN_ABDOMEN numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Head COMP_PAIN_HEAD numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
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Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
  
 
Knees COMP_PAIN_KNEE numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
(Lower)back COMP_PAIN_BACK numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Groin COMP_PAIN_GROIN numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Breasts COMP_PAIN_BREASTS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Other location COMP_PAIN_OTH string text  
  
 
Type of pain (defined as)       
  
 
Arthralgia COMP_PAIN_TYPE_ARTHRALGIA numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Cramps COMP_PAIN_TYPE_CRAMP numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Muscle pain COMP_PAIN_TYPE_MUSCLE numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Radiating to legs COMP_PAIN_TYPE_RADIATING numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Other type COMP_PAIN_TYPE_OTH string text  
  
 
Psychological complaints COMP_PSYCH numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Latency time COMP_PSYCH_TIME numeric 
in months (or blank 
if unknown) 
  
 
Depressive feelings COMP_PSYCH_DEPRESSION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Dizziness COMP_PSYCH_DIZZINESS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Intolerant to noises COMP_PSYCH_NOISES numeric 1 (=YES), 0 (=NO), 
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Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
blank (= unknown) 
  
 
Increase/decrease of weight COMP_PSYCH_WEIGHT numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Loss of libido COMP_PSYCH_LIBIDO numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Nausea COMP_PSYCH_NAUSEA numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Tiredness COMP_PSYCH_TIREDNESS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Restless feelings COMP_PSYCH_RESTLESSNESS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Insomnia COMP_PSYCH_INSOMNIA numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Mood swings or emotionaly out of balance COMP_PSYCH_MOODSWINGS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Memory loss or concentration problems COMP_PSYCH_MEMORY numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Brain fog COMP_PSYCH_BRAINFOG numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Other complaints COMP_OTH numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Latency time COMP_OTH_TIME string 
in months (or blank 
if unknown) 
  
 
Adenomyosis COMP_OTH_ADENOMYOSIS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Always feeling cold COMP_OTH_COLD numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Anemia COMP_OTH_ANEMIA numeric 1 (=YES), 0 (=NO), 
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Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
blank (= unknown) 
  
 
Brittle nails COMP_OTH_NAILS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Swollen abdomen COMP_OTH_SWOLLEN_ABDOMEN numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Hair problems (e.g. hairloss) COMP_OTH_HAIR numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Arrhythmia COMP_OTH_ARRHYTHMIA numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Coughing COMP_OTH_COUGHING numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Vaginal secretion (e.g. much secretion) COMP_OTH_SECRETION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Weakness or asthenia COMP_OTH_ASTHENIA numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Unwished pregnancy COMP_OTH_PREGNANCY numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Menopause complaints COMP_OTH_MENOPAUSE numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Tooth problems COMP_OTH_TEETH numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Fungal infections (vaginal or other) COMP_OTH_FUNGAL_INFECTION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Vitamine defficiency COMP_OTH_VITAMINE numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Fluid in uterus COMP_OTH_FLUID_UTERUS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Vision problems COMP_OTH_VISION numeric 1 (=YES), 0 (=NO), 
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Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
blank (= unknown) 
  
 
Heavier menstruation (if patient is not specific 
about pain or bleedings) COMP_OTH_MENSTUATION numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Excessive sweating COMP_OTH_SWEATING numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Tingling (hands, feets, legs and arms) COMP_OTH_TINGLING numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Feeling the implant COMP_OTH_IMPLANT numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Tinnitus COMP_OTH_TINNITUS numeric 
1 (=YES), 0 (=NO), 
blank (= unknown) 
    Others COMP_OTH_OTH string 
text (add here 
complaints not 
mentioned before) 
Influence on 
daily life INFL_ 
Problems with movenents (e.g. walking, biking, 
doing sports etc) INFL_MOVE numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Work-related problems INFL_WORK numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Problems with daily tasks (e.g. at home) INFL_TASKS numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Relation and/or family problems INFL_RELATION numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Social activities and happiness (incl burnout) 
INF_MOOD_HAPPINESS_SOCIAL (inclusief 
burnout) numeric  
2 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Others INFL_OTH numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
   If other, which ones? INFL_OTH_TXT string text 
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Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
Action taken ACT_ No action ACT_NONE numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Contacted a doctor ACT_DOCTOR numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Visited a gynecologist ACT_DOCTOR_GYNECOLOGIST numeric  
2 (=YES), 0 (=NO), 
blank (= unknown) 
   Other action ACT_OTHER string text 
Tests 
conducted RES_ Hysterosalpingography RES_HYSTEROSALPINGOGRAPHY numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Control position Essure RES_ CONTROL_POSITION numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
If so, through echo RES_POSITION_ECHO numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
If so, through laparoscopy RES_POSITION_LAPAROSCOPY numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Blood test RES_BLOOD numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Other RES_OTH numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
If so, which ones? RES_OTH_TXT string text  
  
 
Result after tests: nothing found RES_RES_NONE numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Result after tests: diagnosis RES_RES_DIAG numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
If so, which ones? RES_DIAG_TEXT string text  
Problems with IMPL_ Perforation IMPL_PERFORATION numeric  1 (=YES), 0 (=NO), 
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Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
implant blank (= unknown) 
  
 
Migration of implant IMPL_MIGRATION numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Breaking of implant IMPL_BREAKING numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
Treatment 
complaints TREAT_ Treatment performed TREAT_PERF numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Medication TREAT_PERF_MED numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Other TREAT_PERF_OTH string text  
  
 
Removal of Essure TREAT_PERF_REMOVAL_ESSURE numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Date removal Essure TREAT_PERF_REMOVAL_ESSURE_DATE numeric format DD/MM/YYYY 
   What was removed together with Essure?       
  
 
One follopian tube TREAT_PERF_REMOVAL_ESSURE_1TUBE numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Two follopian tubes TREAT_PERF_REMOVAL_ESSURE_2TUBES numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Uterus TREAT_PERF_REMOVAL_ESSURE_UTERUS numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Ovary TREAT_PERF_REMOVAL_ESSURE_OVARY numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Novasure conducted TREAT_PERF_NOVASURE numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
   Result        
  
 
Recovered TREAT_PERF_RESULT_RECOVERED numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
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Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
  
 
Recoverring (treatment is performed but it is not 
known yet if patient will fully recover) TREAT_PERF_RESULT_RECOVERING numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Not recovered TREAT_PERF_RESULT_NOT_RECOVERED numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Deceased TREAT_PERF_RESULT_DECEASED numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Treatment planned TREAT_PLANNED numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Medication TREAT_PLANNED_MED numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Other TREAT_PLANNED_OTH string text  
  
 
Removal of Essure TREAT_PLANNED_REMOVAL_ESSURE numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Date removal Essure TREAT_PLANNED_REMOVAL_ESSURE_DATE numeric format DD/MM/YYYY 
   What will be removed together with Essure?       
  
 
One follopian tube TREAT_PLANNED_REMOVAL_ESSURE_1TUBE numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Two follopian tube TREAT_PLANNED_REMOVAL_ESSURE_2TUBES numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Uterus TREAT_PLANNED_REMOVAL_ESSURE_UTERUS numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Ovary TREAT_PLANNED_REMOVAL_ESSURE_OVARY numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Novasure planned TREAT_PLANNED_NOVASURE numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Consider removal of Essure TREAT_CONSIDER_REMOVAL numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
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Type of data 
Variable 
prefix Variable explanation Variable name 
Type of 
variable 
Possible 
values/format 
    
No treatment performed and no treatment 
planned TREAT_NONE numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
Medical 
history HIST_ Nickel allergy HIST_NICKEL numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Suspected nickel allergy HIST_SUSPECTED_NICKEL numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
  
 
Other sterilisation method HIST_OTH_STERILISATION numeric  
1 (=YES), 0 (=NO), 
blank (= unknown) 
   Other HIST_OTH  string text  
Remarks   Relevant remarks REMARKS string text  
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Appendix 3: Onset time of the categories of health problems 
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Appendix 4: Frequency of occurrence of all health problems  
  
Column Total 
N % Count 
Pain 94,4% 352 
Psychological complaint 90,6% 338 
Other complaints 89,5% 334 
Bleeding 53,9% 201 
Allergies 35,7% 133 
Gastro-intestinal or liver complaints 26,5% 99 
Kidney and urinary tract complaints 23,1% 86 
   
  
Column Total 
N % Count 
ALLERGIES 35,7% 133 
Itching skin 15,8% 59 
Allergic complaints in eyes (e.g. red, dry 
or thick eyes) 10,2% 38 
Rash 7,8% 29 
Eczema 6,4% 24 
Allergy for products (e.g. shampoos, 
parfume) 2,9% 11 
Urticaria 0,3% 1 
      
BLEEDING 53,9% 201 
Increase or heavy blood loss during 
menstruation 36,7% 137 
Irregular bleeding or breakthrough 
bleeding 20,1% 75 
Blood loss during coitus 5,1% 19 
      
GASTRO-INTESTINAL OR LIVER 
COMPLAINTS 26,5% 99 
Constipation 4,6% 17 
Strange taste in mouth (e.g. metal taste) 4,0% 15 
Bile problems 2,9% 11 
Thin stool 2,7% 10 
Liver problems 1,6% 6 
Smelly breath 0,5% 2 
      
KIDNEY AND URINARY TRACT 
COMPLAINTS 23,1% 86 
Problems with urinating (often/less, 
difficult) 9,1% 34 
Bladder infection 7,0% 26 
Incontinence 6,7% 25 
Adrenal exhaustion 0,8% 3 
Dark urine 0,3% 1 
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Column Total 
N % Count 
PAIN 94,4% 352 
During ovulation 23,3% 87 
During menstruation 16,4% 61 
During coitus 12,9% 48 
      
Abdomen 51,5% 192 
(Lower)back 48,5% 181 
Head 31,4% 117 
Pelvis/hips 28,4% 106 
Legs 22,8% 85 
Groin 12,6% 47 
Breasts 8,6% 32 
Knees 2,9% 11 
Other location 21,7% 81 
      
Arthralgia 30,6% 114 
Muscle pain 13,4% 50 
Cramps 12,1% 45 
Radiating to legs 10,7% 40 
 
  
Column Total 
N % Count 
PSYCHOLOGICAL COMPLAINTS 90,6% 338 
Tiredness 70,2% 262 
Mood swings or emotionaly out of balance 39,9% 149 
Memory loss or concentration problems 38,9% 145 
Depressive feelings 21,2% 79 
Increase/decrease of weight 19,6% 73 
Insomnia 17,2% 64 
Loss of libido 15,0% 56 
Dizziness 12,6% 47 
Restless feelings 8,6% 32 
Nausea 8,3% 31 
Brain fog 7,5% 28 
      
OTHER COMPLAINTS 89,5% 334 
Tingling (hands, feets, legs and arms) 20,4% 76 
Heavier menstruation (if patient is not 
specific about pain or bleedings) 18,5% 69 
Excessive sweating 18,0% 67 
Swollen abdomen 16,9% 63 
Menopause complaints 16,4% 61 
Hair problems (e.g. hairloss) 13,7% 51 
Arrhythmia 11,3% 42 
Vaginal secretion (e.g. much secretion) 11,3% 42 
Fungal infections (vaginal or other) 11,3% 42 
Vision problems 11,3% 42 
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Column Total 
N % Count 
Feeling the implant 8,8% 33 
Vitamine defficiency 7,0% 26 
Tinnitus 5,4% 20 
Tooth problems 4,0% 15 
Weakness or asthenia 2,4% 9 
Anemia 2,7% 10 
Always feeling cold 1,9% 7 
Coughing 1,6% 6 
Brittle nails 1,3% 5 
Unwished pregnancy 0,3% 1 
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Appendix 5: Age of women at the onset of health problems 
  Age 
  n Mean SD 
All women in the study 229a 38 5 
Women without psychological complaints 25a 39 5 
Women with psychological complaints 75b 38 5 
Women with tiredness 52b 38 5 
Women with mood swings or emotionally 
out of balance 26
b 39 3 
Women with memory loss or concentration 
problems 34
b 39 4 
Women with depressing feelings 19b 38 6 
Women with increase or decrease in weight 15b 39 5 
Women with insomnia 15b 41 5 
Women with loss of libido 12b 37 7 
Women with dizziness 8b 38 4 
a) number of women for which the age when complaints started (not specified per 
complaint) is known 
b)  number of women for which the age when the specific psychological complaint started 
is known 
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Appendix 6: Data on medical consultation 
  % of total 
No contact with 
doctor/specialist 1% 
Visited a doctor/specialist 90% 
Visited a gynecologist 21% 
    
Test performed 53% 
Control position Essure 9% 
Echo 6% 
Laparoscopy 1% 
Hysterosalpingography 2% 
Blood test 22% 
Other test 37% 
 
  % of total 
Result after tests: 
nothing found 14% 
Result after tests: 
diagnosis 13% 
    
Perforation 1,6% 
Migration of implant 3,8% 
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Appendix 7: Prevalence of health problems before removal 
of Essure® 
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